免疫原性
免疫系统
癌症
肿瘤免疫学
医学
免疫疗法
免疫学
癌症研究
内科学
作者
Thomas Blankenstein,Pierre G. Coulie,Eli Gilboa,Elizabeth M. Jaffee
出处
期刊:Nature Reviews Cancer
[Springer Nature]
日期:2012-03-01
卷期号:12 (4): 307-313
被引量:368
摘要
Four leading tumour immunologists provide their opinions on the determinants of immunogenicity and how we might therapeutically improve tumour immunogenicity in the future. Many standard and targeted therapies, as well as radiotherapy, have been shown to induce an anti-tumour immune response, and immunotherapies rely on modulating the host immune system to induce an anti-tumour immune response. However, the immune response to such therapies is often reliant on the immunogenicity of a tumour. Tumour immunogenicity varies greatly between cancers of the same type in different individuals and between different types of cancer. So, what do we know about tumour immunogenicity and how might we therapeutically improve tumour immunogenicity? We asked four leading cancer immunologists around the world for their opinions on this important issue.
科研通智能强力驱动
Strongly Powered by AbleSci AI